Successful Salvage of Very Early Relapse in Pediatric Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin and HLA-haploidentical Peripheral Blood Stem Cell Transplantation With Posttransplant Cyclophosphamide.

Abstract

Herein, we describe a 14-year-old female patient with B-cell precursor acute lymphoblastic leukemia who relapsed in early consolidation. Minimal residual disease-negative complete remission was obtained after 1 cycle of inotuzumab ozogamicin therapy. She underwent HLA-haploidentical peripheral blood stem cell transplantation after a myeloablative conditioning regimen. Posttransplant cyclophosphamide, tacrolimus, and mycophenolate mofetil were administered for the prophylaxis of graft-versus-host disease. At 23 months, she was in complete remission. Although the administration of inotuzumab ozogamicin followed by haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide has been limited in children, this strategy may be an effective treatment for pediatric refractory acute lymphoblastic leukemia.

• Authors: Takanari Abematsu, Takuro Nishikawa, Shunsuke Nakagawa, Yuichi Kodama, Yasuhiro Okamoto, Yoshifumi Kawano
• Journal: Journal of pediatric hematology/oncology (J Pediatr Hematol Oncol) Vol. 44 Issue 2 Pg. 62-64 (03 01 2022) ISSN: 1536-3678 [Electronic] United States
• PMID: 33512872 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Chemical References

• Cyclophosphamide
• Inotuzumab Ozogamicin

Topics

• Adolescent
• Child
• Cyclophosphamide (therapeutic use)
• Female
• Hematopoietic Stem Cell Transplantation
• Humans
• Inotuzumab Ozogamicin
• Peripheral Blood Stem Cell Transplantation
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy)
• Recurrence